Engineered immune cells take aim at tough childhood leukemia
NCT ID NCT03241940
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to standard treatments. The goal is to find the best dose and see how safe and effective this approach might be.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19/CD22 chimeric antigen receptor (CAR) T cells
- What this could lead to
- If successful, this approach could offer a new treatment option for children and young adults with hard-to-treat B-cell leukemia.
- What could go wrong
- This is an early-phase trial, so the therapy may not work for everyone and could cause serious side effects like cytokine release syndrome or neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Blood test may end painful bone marrow biopsies for myeloma patients
- Precision radiation may boost stem cell transplant success in tough leukemias
- Scientists build a biobank to crack the mystery of CAR-T cell failure